Moderna sued Pfizer and BioNTech on Aug. 26, alleging the companies infringed on its patents for technology utilized by COVID-19 vaccines.
Pfizer Inc. and French biotech company Valneva SE are launching a phase 3 clinical study to test an experimental vaccine against Lyme disease, the companies announced on Aug. 8.
Pfizer Inc. said on Thursday it is seeking full U.S. approval for its oral COVID-19 antiviral treatment Paxlovid, which is currently available under an emergency use authorization (EUA).
The Biden administration said it has signed a new agreement with Pfizer and partner BioNTech for 105 million doses of their COVID-19 vaccine for a fall vaccination campaign, with the deal worth $3.2 billion.
Pfizer and BioNTech plan on asking the U.S. Food and Drug Administration (FDA) to grant emergency use authorization for a booster for their COVID-19 vaccine for children aged 5- to 11-years-old, the companies announced on April 14.
Pfizer said on Monday that it is voluntarily recalling some of its blood pressure drug products and two authorized cheaper generic versions of the drug due to elevated levels of a potentially cancer-causing impurity.
Pfizer’s COVID-19 vaccine was not effective in preventing infection among children aged 5 to 11, according to a new study.
A former clinical trial overseer for a contractor holding trials of Pfizer’s COVID-19 vaccine is pressing forward with a lawsuit against Pfizer and her former company despite the U.S. government declining to side with her.
Pfizer on Tuesday said it expects to see continued demand for its products this year, forecasting $54 billion in combined sales of its COVID-19 vaccine shots and antiviral pills.
A group seeking all the documents analyzed by U.S. drug regulators before approving Pfizer’s COVID-19 vaccine has reached an agreement with the government on how fast the documents will be produced.
Pfizer has asked a federal court to let it intervene in a high-profile case that has seen U.S. drug regulators try to slow-walk disclosure of data on Pfizer’s COVID-19 vaccine.
Dr. Scott Gottlieb, former director of the Food and Drug Administration (FDA) and current board member at Pfizer, said that declining COVID-19 cases should signal to policymakers that it is time to lift more pandemic-related restrictions.